GOG-3082 - Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma Endometrial Adenocarcinoma and Urothelial Carcinoma Based on Acrivon OncoSignature Status

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Endometrial Adenocarcinoma
    Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Uterine Cancer, Endometrial Cancer
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Female
  • Other Inclusion Criteria:
    1. To participate in the study the following conditions must be met:
    2. Patient must have cancer that is confirmed by a biopsy and is either locally advanced, meaning it can't be cured by surgery or radiation, or has spread to other parts of the body. The cancer must have gotten worse while receiving or after trying at least one treatment before.
    3. Patient must agree to give a sample of their tumor tissue for testing with a new biopsy, which will be taken from a location that has not been previously treated with radiation therapy.

You may not be eligible for this study if the following are true:

    1. You will not be able to participate in the study if you have had:
    2. Patients who have known brain metastases that are causing symptoms and require a high dose of prednisolone (or a similar medication) exceeding 10 milligrams per day.
    3. Patients who have not fully recovered from the side effects of previous anti-cancer treatments.



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.